Douglas L. Mayers

6.7k citations

90 papers · 3.9k indexed · h-index 30

Impact in

Virology top 0.2%
- HIV Research and Treatment
Infectious Diseases top 0.2%
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions

Papers in

Virology 51
- HIV Research and Treatment 50
Infectious Diseases 68
- HIV/AIDS drug development and treatment 61
- HIV/AIDS Research and Interventions 37

Co-authors: John D. Baxter Blasé A. Carabello R. Brad Stamm Randolph P. Martin Donald I. Abrams Thomas C. Merigan Marie L. Hoover Deborah Wentworth
Journals: Journal of Hepatology (8 papers)Antimicrobial Agents and Chemotherapy (8 papers)Clinical Infectious Diseases (6 papers)JAIDS Journal of Acquired Immune Deficiency Syndromes (5 papers)AIDS (4 papers)
Partner nations: United States Germany Canada

In The Last Decade

Douglas L. Mayers

90 papers receiving 3.7k citations

Peers

Countries citing papers authored by Douglas L. Mayers

Since Specialization

Citations

This map shows the geographic impact of Douglas L. Mayers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas L. Mayers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas L. Mayers more than expected).

Fields of papers citing papers by Douglas L. Mayers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas L. Mayers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas L. Mayers. The network helps show where Douglas L. Mayers may publish in the future.

Co-authors

The 25 scholars most cited alongside Douglas L. Mayers, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Douglas L. Mayers Line = papers co-authored together Douglas L. Mayers links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Drug interaction profile for GSK2248761, a next generation non‐nucleoside reverse transcriptase inhibitor British Journal of Clinical Pharmacology ·Monica Mitta, Joseph Kim, Elizabeth Gould, Yu Lou, Teresa Agudo López, S Ibishi, Mark R. Johnson, Xiao‐Jian Zhou, Keith Pietropaolo, Douglas L. Mayers	2012	11
2	Microdose Pharmacokinetics of IDX899 and IDX989, Candidate HIV‐1 Non‐Nucleoside Reverse Transcriptase Inhibitors, Following Oral and Intravenous Administration in Healthy Male Subjects The Journal of Clinical Pharmacology ·Xiao‐Jian Zhou, R. Colin Garner, Lamiaa M. R. Khalak, Christian Kissling, Douglas L. Mayers	2009	61
3	Absence of Effect of Telbivudine on Cardiac Repolarization: Results of a Thorough QT/QTc Study in Healthy Participants The Journal of Clinical Pharmacology ·Fred Poordad, 重松宏, Stuart Harris, Behzad Rajabian, Moti Daswani, Douglas L. Mayers, Xiao‐Jian Zhou	2009	7
4	Efficacy And Safety of Three Doses of Tipranavir Boosted with Ritonavir in Treatment-Experienced HIV Type 1-Infected Patients AIDS Research and Human Retroviruses ·Joseph Gathe, Gerald Pierone, Peter J. Piliero, Keikawus Arastéh, Rafael Rubio, Richard Lalonde, David A. Cooper, Adriano Lazzarin, Veronika Kohlbrenner, 洲崎哲行, John P. Sabo, Douglas L. Mayers	2007	19
5	Long-Term Efficacy and Safety of Tipranavir Boosted With Ritonavir in HIV-1-Infected Patients Failing Multiple Protease Inhibitor Regimens JAIDS Journal of Acquired Immune Deficiency Syndromes ·Martin Markowitz, Leonard N. Slater, Robert A. Schwartz, Powel Kazanjian, Xinping Yu, David A. Wheeler, Mitchell Goldman, Dietmar Neubacher, Douglas L. Mayers, Hernán Valdez, Scott McCallister	2007	16
6	HIV‐1 Drug Resistance in Variants from the Female Genital Tract and Plasma The Journal of Infectious Diseases ·Kimdar Sherefa Kemal, Harold Burger, Douglas L. Mayers, Kathryn Anastos, Brian Foley, Christina M. Ramirez, Wang Yuanping, Claudia Matuschek, Gastón Picchio, Dong-Min JANG, Wei Gao, William A. Meyer, Barbara Weiser	2007	27
7	Disadvantages of Structured Treatment Interruption Persist in Patients With Multidrug-Resistant HIV-1 JAIDS Journal of Acquired Immune Deficiency Syndromes ·Jody Lawrence, Katherine Huppler Hullsiek, Lisa Thackeray, Donald I. Abrams, Lawrence R. Crane, Douglas L. Mayers, Michael C. Jones, Salsabila Nariyah, Barry Schmetter, John D. Baxter	2006	17
8	Seeking Ethical Designs for HIV Clinical Trials in Treatment-Experienced Patients: An Industry Perspective AIDS Research and Human Retroviruses ·Douglas L. Mayers, Jain Chung, Veronika Kohlbrenner, David B. Hall, Ralph DeMasi, Dietmar Neubacher, Neil Buss, Miklos Salgo	2006	1
9	Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials The Lancet ·Charles B. Hicks, Pedro Cahn, David A. Cooper, Sharon Walmsley, Christine Katlama, Bonaventura Clotet, Adriano Lazzarin, Margaret Johnson, Dietmar Neubacher, Douglas L. Mayers, Hernan Valdez	2006	242
10	Efficacy of the Protease Inhibitors Tipranavir plus Ritonavir in Treatment-Experienced Patients: 24-Week Analysis from the RESIST-1 Trial Clinical Infectious Diseases ·Joseph Gathe, David A. Cooper, Charles Farthing, Dushyantha Jayaweera, Y. Matsuzawa, Gerald Pierone, Crystal Mackall, Benoît Trottier, Sharon Walmsley, Cassy Workman, Geoffrey Mukwaya, Veronika Kohlbrenner, 洲崎哲行, Scott McCallister, Douglas L. Mayers, (unknown)	2006	67
11	Treatment of Primary Human Immunodeficiency Virus Type 1 Infection with Potent Antiretroviral Therapy Reduces Frequency of Rapid Progression to AIDS The Journal of Infectious Diseases ·M. Michelle Berrey, Timothy W. Schacker, Ann C. Collier, Theresa Shea, Scott J. Brodie, Douglas L. Mayers, Robert W. Coombs, John N. Krieger, Tae‐Wook Chun, Anthony S. Fauci, Steven G. Self, Lawrence Corey	2001	94
12	Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use AIDS ·Horacio Salomón, Mark A. Wainberg, Bluma Brenner, Yudong Quan, Danielle Rouleau, Pierre Côté, Roger LeBlanc, Éric Lefebvre, Bonnie Spira, 知雄福田, R P Sékaly, Brian Conway, Douglas L. Mayers, Jean‐Pierre Routy	2000	180
13	A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy AIDS ·John D. Baxter, Douglas L. Mayers, Deborah Wentworth, James D. Neaton, Marie L. Hoover, Mark A. Winters, Sharon Mannheimer, Melanie Thompson, Donald I. Abrams, Barbara Brizz, John P. A. Ioannidis, Thomas C. Merigan	2000	379
14	Stavudine‐Induced Macrocytosis During Therapy for Human Immunodeficiency Virus Infection Clinical Infectious Diseases ·Gregory Martin, David L. Blazes, Douglas L. Mayers, Katherine Spooner	1999	12
15	Primary Lamivudine Resistance in Acute/Early Human Immunodeficiency Virus Infection Clinical Infectious Diseases ·Brian Conway, Valentina Montessori, Danielle Rouleau, Elena Montacchini, M. V. O'Shaughnessy, Signe Fransen, D M Phillips, O. S. Weislow, Douglas L. Mayers	1999	12
16	EXOTIC VIRUS INFECTIONS OF MILITARY SIGNIFICANCE Dermatologic Clinics ·Douglas L. Mayers	1999	3
17	Quantitative Relationship of Circulating p24 Antigen with Human Immunodeficiency Virus (HIV) RNA and Specific Antibody in HIV-Infected Subjects Receiving Antiretroviral Therapy The Journal of Infectious Diseases ·Arthur E. Brown, Maryanne Vahey, Susan Zhou, Argelia Álvarez Roíz, Nancy Ruíz, S. Voss, James R. Lane, Douglas L. Mayers, (unknown)	1995	21
18	In vitro susceptibility of clinical isolates of HIV-1 to XM323, a non-peptidyl HIV protease inhibitor AIDS ·Dean L. Winslow, Douglas L. Mayers, Helen Scarnati, James R. Lane, Elizabeth Findlay, Michaël Otto	1994	5
19	Primary Infection with Zidovudine-Resistant Human Immunodeficiency Virus Type 1 New England Journal of Medicine ·Alejo Erice, Douglas L. Mayers, David G. Strike, Kim Sannerud, Francine E. McCutchan, Keith Henry, Henry H. Balfour	1993	191
20	Incidence of human immunodeficiency virus seroconversion in US Navy and Marine Corps personnel, 1986 through 1988. PubMed ·Frank C. Garland, Douglas L. Mayers, Oindrila Banerjee, Gy-ne. Beczassy, Falko Schmidt, Edward D. Gorham, Sunny Pahlajani, Michael M. McNally	1989	23

About Douglas L. Mayers

Douglas L. Mayers is a scholar working on Virology, Infectious Diseases, Hepatology, Epidemiology and Molecular Medicine, having authored 90 papers that have together received 3.9k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (61 papers), HIV Research and Treatment (50 papers), HIV/AIDS Research and Interventions (37 papers), Hepatitis C virus research (17 papers), Hepatitis B Virus Studies (11 papers), Cytomegalovirus and herpesvirus research (7 papers), Biochemical and Molecular Research (6 papers) and Pneumocystis jirovecii pneumonia detection and treatment (6 papers). The work is most often cited by research in Virology (2.5k citations), Infectious Diseases (2.9k citations), Hepatology (412 citations), Emergency Medicine (272 citations) and Epidemiology (802 citations). Douglas L. Mayers has collaborated with scholars based in United States, Germany and Canada. Frequent co-authors include John D. Baxter, Blasé A. Carabello, R. Brad Stamm, Randolph P. Martin, Donald I. Abrams, Thomas C. Merigan, Marie L. Hoover, Deborah Wentworth, James D. Neaton and Mark A. Winters. Their work appears in journals such as Journal of Hepatology, Antimicrobial Agents and Chemotherapy, Clinical Infectious Diseases, JAIDS Journal of Acquired Immune Deficiency Syndromes and AIDS.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact